PMID- 35723554
OWN - NLM
STAT- MEDLINE
DCOM- 20220622
LR  - 20230322
IS  - 1541-2563 (Electronic)
IS  - 1541-2563 (Linking)
VI  - 19
IP  - 1
DP  - 2022
TI  - Effects of Phosphodiesterase-5 Inhibitors in Patients with Chronic Obstructive 
      Pulmonary Disease: A Systematic Review and Meta-Analysis.
PG  - 300-308
LID - 10.1080/15412555.2022.2067525 [doi]
AB  - Chronic obstructive pulmonary disease (COPD) is a major burden of healthcare 
      worldwide. We aimed to determine the effects of PDE-5 inhibitors on clinical 
      outcomes and haemodynamic parameters in patients with COPD. A PROSPERO-registered 
      systematic review and meta-analysis (identification number CRD42021227578) were 
      performed to analyse the effects of PDE-5 inhibitors in patients with COPD. Data 
      were sourced from MEDLINE, EMBASE, Cochrane Register of Controlled Trials and 
      "ClinicalTrials.gov." Randomised controlled trials (RCTs) comparing PDE-5 
      inhibitors with control in patients with COPD were included. Quality assessment 
      was carried out using the Cochrane Collaboration's tool for assessing the risk of 
      bias in randomised trials. The pooled mean difference of 6-minute walk distance 
      (6MWD) and mean pulmonary arterial pressure based on inverse variance estimation 
      were analysed with a fixed-effect model or random-effects model meta-analysis. 
      Nine RCTs involving 414 patients were included in the review. There was no 
      significant difference in 6MWD (mean difference = 22.06 metres, 95% confidence 
      interval (CI), -5.80 to 49.91). However, there was a statistically significant 
      difference between PDE-5 inhibitor and control groups in mean pulmonary artery 
      pressure (mean difference = -3.83 mmHg, 95% CI, -5.93 to -1.74). Headaches were 
      the most common adverse event, occurring significantly in the PDE-5 inhibitor 
      intervention group (odds ratio 3.83, 95% CI, 1.49 to 9.86). This systematic 
      review indicates that PDE-5 inhibitors do not improve exercise capacity despite 
      some possible improvements in haemodynamic parameters in COPD patients.
FAU - Isa, Nafeesah
AU  - Isa N
AD  - Research Department of Practice and Policy, School of Pharmacy, University 
      College London, London, UK.
FAU - Mudhafar, Durrah
AU  - Mudhafar D
AD  - Research Department of Practice and Policy, School of Pharmacy, University 
      College London, London, UK.
FAU - Ju, Chengsheng
AU  - Ju C
AD  - Research Department of Practice and Policy, School of Pharmacy, University 
      College London, London, UK.
FAU - Man, Kenneth K C
AU  - Man KKC
AD  - Research Department of Practice and Policy, School of Pharmacy, University 
      College London, London, UK.
AD  - Centre for Safe Medication Practice and Research, Department of Pharmacology and 
      Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 
      SAR, China.
FAU - Lau, Wallis C Y
AU  - Lau WCY
AD  - Research Department of Practice and Policy, School of Pharmacy, University 
      College London, London, UK.
AD  - Centre for Safe Medication Practice and Research, Department of Pharmacology and 
      Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 
      SAR, China.
FAU - Cheng, Lok Yin
AU  - Cheng LY
AD  - Department of Respiratory Medicine, South Warwickshire NHS Foundation Trust, 
      Warwick, UK.
FAU - Wei, Li
AU  - Wei L
AD  - Research Department of Practice and Policy, School of Pharmacy, University 
      College London, London, UK.
LA  - eng
GR  - G106/1249/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - England
TA  - COPD
JT  - COPD
JID - 101211769
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - EC 3.1.4.35 (Cyclic Nucleotide Phosphodiesterases, Type 5)
SB  - IM
MH  - Cyclic Nucleotide Phosphodiesterases, Type 5
MH  - Humans
MH  - Phosphodiesterase 5 Inhibitors/therapeutic use
MH  - *Pulmonary Disease, Chronic Obstructive/drug therapy
MH  - Quality of Life
MH  - Walking
OTO - NOTNLM
OT  - COPD
OT  - PDE-5 inhibitor
OT  - pulmonary hypertension
OT  - systematic review
EDAT- 2022/06/21 06:00
MHDA- 2022/06/23 06:00
CRDT- 2022/06/20 09:43
PHST- 2022/06/20 09:43 [entrez]
PHST- 2022/06/21 06:00 [pubmed]
PHST- 2022/06/23 06:00 [medline]
AID - 10.1080/15412555.2022.2067525 [doi]
PST - ppublish
SO  - COPD. 2022;19(1):300-308. doi: 10.1080/15412555.2022.2067525.